1 / 30

Expanding opportunities

Expanding opportunities. Our purpose. Providing affordable and innovative medicines for healthier lives. An emerging global pharmaceutical company. Established in 1984, we are a fully integrated global pharmaceutical company through three core businesses:

elle
Download Presentation

Expanding opportunities

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Expandingopportunities

  2. Our purpose Providing affordableand innovativemedicines for healthier lives.

  3. An emerging global pharmaceutical company Established in 1984, we are a fully integrated global pharmaceutical company through three core businesses: • Pharmaceutical Services and Active Ingredients - comprising of our Active Pharmaceutical Ingredients and Custom Pharmaceutical Services business • Global Generics - which includes Branded and Unbranded generics • Proprietary Products - which includes New Chemical Entities (NCEs), Differentiated Formulations, TM Generic Biopharmaceuticals and a Dermatology focused Specialty company - Promius Pharma Our products are marketed globally, with a strong focus on India, Russia, Europe and US. Dr. Reddy's conducts NCE research in the areas of metabolic disorders, cardiovascular diseases, anti-infectives and pain/ inflammation

  4. Indian Pharma Firsts • New York Stock Exchange listing • Sarbanes-Oxley (SOX) certification • 180-days exclusive marketing rights forageneric drug in the US • Authorized Generic • Commencement of Discovery Research • NCE out-licensed for development • NCE into Phase III development • Fastest to reach $1 billion in revenues • HDMA Diana Award winner (2006, 2007 and 2008) • United States Custom and Border Protection Agency certification

  5. Global Pharma Firsts • USP certification under the Pharmaceutical Ingredient Verification Program • Launch of generic monoclonal antibody • Polypill (Cardiovascular) Trial

  6. Driving value through collaboration The foundation of our partnership philosophy: • Diversified business model; multiple product and service offerings • A simple, transparent and streamlined process to progress partnering discussions • Centralized Business Development Council to facilitate thorough diligence of multiple partnership opportunities and coordination between the different business units • Flat organizational structure to facilitate swift decision making • Effective alliance management processes • Adherence to highest global regulatory standards

  7. Alliance management Deal Execution, Alliance Management and Value Realization 3 Evaluation, Negotiation and Due-Diligence 2 The partnership process Preliminary Contact & Opportunity Screening 1

  8. Global Generics Our Branded and Unbranded generic products offer affordable alternatives to innovator brands, both directly and through key partnerships

  9. Global Generics Manufacturing Bandwidth • 7 Formulation plants [6 in India (1 USFDA approved), 1 in US] Product Portfolio • Integrated product development center • 50+ products marketed in the US • 130+ ANDAs filed till date. 69 ANDAs pending approval at the USFDA, of which 32 are Para IV and 19 are FTFs* • 160+ products marketed in the EU • 200+ branded formulations marketed in India, Russia and other emerging markets • Among the top 10 generic companies in the US; ranks 5 in Germany; the 7th largest Generic Pharma company in Russia and among the largest pharma companies in India * As on Q3 FY09

  10. Unbranded Generics We have a significant presence in the regulated markets of USA, Germany and UK where we offer high quality medicines at affordable prices

  11. Unbranded Generics Strengths • World-class distribution capabilities • Strong product portfolio and an attractive pipeline • Proven ability to garner market share • Credible track record of successful “Day 1” launches • Strong relationships with key distributors, pharmacy chains and insurance funds Partnering Opportunities • In-licensing, co-development and product opportunities in difficult-to-make generics • Product portfolio expansion • Partners with unique platform technologies for product development

  12. Branded Generics Our Branded Generics portfolio offers over 200 products in the major therapeutic areas of gastro-intestinal, cardiovascular, pain management, oncology, anti- infectives, paediatrics and dermatology. Our top brands enjoy leadership positions in our key markets of India, Russia & the CIS, Romania and Venezuela

  13. Branded Generics India • Among the largest pharmaceutical companies • Product portfolio of over 200 brands across 13 therapeutic areas • Market leader in gastro-intestinal, cardiovascular, pain management and oncology • 2000+ sales and marketing team • 300,000+ doctors and 1900+ stockist • Near 100% coverage of KOLs and key institutes • Stamlo, Omez, Reditux, Nise, Ketorol are market leaders in their respective category

  14. Branded Generics (Contd.) Russia • Among the top 15th pharma companies. 14th in retail segment • Fastest growing international branded generic company by volumes • Top 5 brands occupy the 1 spot in their respective molecule space • 4 brands [Omez, Ketorol, Nise and Ciprolet] among Top 100 • Strong presence in gastro-intestinal, cardiovascular, anti-Infective, oncology, pain and dermatology • Building capabilities in wellness and nutraceuticals • 300 + sales and marketing team • Working with top 5 distributors • Coverage of 66 town classes, 50800 doctors, 20000 retailers and 500 hospitals

  15. Branded Generics (Contd.) Partnering Opportunities • In-licensing opportunities in Differentiated Products and NCEs (phase III, registered, marketed) in gastro- intestinal, cardiovascular, metabolic disorders, pain, anti-infectives and dermatology • Partnerships to build Hospital and Paediatric portfolio • Life cycle management opportunities for big brands

  16. Global Oncology Strengths • One stop portfolio solution with a broad product basket for launches across the globe • Established capabilities in chemistry and biology enabling strong IP positions • Low cost development and manufacturing operations • Strong commercial infrastructure in focus Geographies • Partnering opportunities • Partners for commercialization of our portfolio • In-licensing opportunities in: • - Differentiated Products and NCEs (phase III, registered, marketed) • - Complimentary basket of oncology products • Co-development opportunities for big brands

  17. Pharmaceutical Services &Active Ingredients The Pharmaceutical Services and Active Ingredients business of Dr. Reddy's serves Generics and Innovator companies through the Active Pharmaceutical Ingredients (API) and Custom Pharmaceutical Services (CPS) businesses respectively

  18. Pharmaceutical Services &Active Ingredients • Manufacturing Bandwidth • 8 USFDA approved facilities (6 in India, 1 in Mexico and 1 in UK) • 3 Technology Development Centers (2 in India and 1 in UK) • Among the top three API players globally • Product Portfolio • 150+ APIs in the market • 20 products under development at any given point of time • IP leveraged wide basket of assets • Cost effective API pipeline; end-to-end services andcompetitive pricing

  19. Active PharmaceuticalIngredients (API) We offer an unparalleled portfolio to our customers, who include innovators and generic formulators worldwide. With more than 150 products, including cytotoxic and hormones, and our “first in, last out” approach, we are among the top three API players globally

  20. Active PharmaceuticalIngredients (API) Strengths • Broad Global Portfolio: Portfolio of 140+ USDMFs, 80+ EDMFs and several filings in the Rest-of-the-World markets • Global Presence: Sales in over 85 countries • Large scale of operations: 8 USFDA approved facilities; serving 300+ SKUs across the globe; unmatched scale-up facilities • Strong product lifecycle management • Cost and technology leadership Partnering Opportunities • Sourcing opportunities for products globally • Technology platforms to achieve breakthrough costs for better life cycle management • Partnerships to build capabilities and strengthen the overall value chain

  21. Custom PharmaceuticalServices (CPS) The CPS business today is a partner of choice for the strategic outsourcing needs of 'Innovators', both big pharma and emerging biotech companies worldwide. Partners will benefit from our years of experience in developing and extending product life cycles and enhancing intellectual property. Our services and capabilities go beyond the boundaries of contract services and enable value creation through different stages of pharmaceutical development.

  22. Custom PharmaceuticalServices (CPS) Strengths: • Cost effectiveness, speed and flexibility in project execution • Broad service offerings • Process development and scale up to commercial manufacturing of drug substance and drug products • Customized solutions with a range of products (APIs and dosage forms) • Technology leveraged manufacturing services including chiral technology (asymmetric hydrogenation, hydroformulation and bio catalysis) • Activated mPEGs/ Pegylation • Steroidal API manufacturing • IP advantaged basket of assets • Partnering Opportunities: • Life cycle management solutions • End-to-End services in development and manufacturing

  23. Proprietary Products Our Proprietary Products business comprises of New Chemical Entities (NCEs), Generic Biopharmaceuticals, Differentiated Formulations and a Dermatology focused Specialty company - Promius Pharma. We are building world-class capabilities and partnerships to accelerate the discovery and development of new and improved therapies in select diseases

  24. Proprietary Products Development and Manufacturing Bandwidth • Discovery Research centers in India and US • cGMP E.Coli and Mammalian cell-culture manufacturing facilities with filling and finishing • Dedicated product development teams for differentiated products and Promius Pharma

  25. Discovery Research Strengths • Discovery and development efforts in metabolic disorders (type 2 diabetes, obesity, dyslipidemia),anti- bacterials and pain/inflammation • History of successful R&D collaborations with external partners • Creative risk-sharing partnerships that leverage strengths in therapeutic areas of focus • Systematic project management principles and processes for timely execution and monitoring of development programs Partnering opportunities • Co-development and commercialization partners for internal programs • In-licensing of drug delivery technology platforms in metabolic disorders, anti- bacterials and pain/inflammation

  26. Biologics We view generic biopharmaceuticals as an integral part of our mid to long term growth strategy and believe that building depth in development and manufacturing capabilities will be critical in accessing this opportunity. We have made significant efforts in this direction and have over the years succeeded in creating world class infrastructure and a highly capable team.

  27. Biologics Strengths • Proven generic biopharmaceutical development capabilities with two marketed products - GrafeelTM (filgrastim) and RedituxTM (rituximab), in emerging markets • Developed and launched RedituxTM (rituximab) - the world's first generic monoclonal antibody • Pipeline of eight generic biopharmaceuticals in various stages of development with two in clinical development • The product portfolio spans multiple therapeutic areas - oncology, auto-immune diseases and CNS • cGMP facilities to manufacture Biologics, in adherence with global regulatory requirements at a significant cost advantage Partnering opportunities • Partners with intent and capabilities to commercialize generic biopharmaceuticals in specific geographies • Partners developing generic biopharmaceuticals as differentiated product or for new indications and want to source product

  28. Promius Pharma Promius Pharma is a branded Specialty company with a portfolio of in-licensed dermatology products and an internal pipeline in different stages of development. Promius Pharma's current portfolio contains innovative products for the treatment of psoriasis, atopic dermatitis and seborrheic dermatitis

  29. Promius Pharma Strengths • 2 products in the market: EpiCeram Skin Barrier Emulsion and Scytera Foam, 7 products in pipeline • Track record of successful partnerships with Ceragenix, Foamix, Sinclair and Antares • Strong portfolio of in-licensed and co-developed dermatological products and an internal pipeline under development • Strong and committed sales force • State-of-the-art integrated product development center in Hyderabad, India Partnering opportunities • In-licensing and product opportunities in branded dermatology space • Interested in late stage (phase II, Phase III, ready-to-market, or in-market) opportunities for development and commercialization • Out-licensing, co-development and commercialization partners for internal programs for market outside of the US

  30. Thank you

More Related